Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34126761.
- Also identified by DOI 10.1161/STROKEAHA.120.033107.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cerebral amyloid angiopathy is a devastating cause of intracerebral hemorrhage for which there is no specific secondary stroke prevention treatment. Here we review the current literature regarding cerebral amyloid angiopathy pathophysiology and treatment, as well as what is known of the fibrinolytic pathway and its interaction with amyloid. We postulate that tranexamic acid is a potential secondary stroke prevention treatment agent in sporadic cerebral amyloid angiopathy, although further research is required.
Medical subject headings
- Antifibrinolytic Agents
- Cerebral Amyloid Angiopathy
- Drug Delivery Systems
- Fibrinolysin